EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. New approaches in treating cancer.
Murch
Lisa
L
lisamurch@gmail.com
D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003503:Cyclobutanes / Q000627:therapeutic use; D053595:Embryonic Stem Cells / Q000637:transplantation; D010450:Endopeptidases / Q000187:drug effects; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D016615:Telomere / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D003503:Cyclobutanes; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D010450:Endopeptidases; D000626:Aminopeptidases; C106541:methionine aminopeptidase 2; D008666:Metalloendopeptidases; C091939:ubiquitin isopeptidase; C066228:lobaplatin